HHS Ends Contracts for mRNA Vaccine Development

The US Department of Health and Human Services (HHS) is ending contracts worth almost $500 million to develop mRNA vaccines, citing a "coordinated wind-down" of Biomedical Advanced Research and Development Authority (BARDA) projects. The move comes under Secretary Robert F. Kennedy Jr., who faces criticism from some supporters who want mRNA vaccines pulled off the market entirely. HHS is shifting funding toward other vaccine programs.

The U.S. Department of Health and Human Services (HHS) has announced a significant shift in its vaccine development strategy, marking a "coordinated wind-down" of its mRNA vaccine projects under the Biomedical Advanced Research and Development Authority (BARDA). This move, which comes under Secretary Robert F. Kennedy Jr., will see the cancellation of contracts worth nearly $500 million, with a focus on redirecting funding toward other vaccine programs [1].

The decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency. According to HHS, the review found that many mRNA vaccines, including those for bird flu, failed to provide effective protection against upper respiratory infections such as COVID-19 and influenza. As a result, HHS is terminating 22 mRNA vaccine development projects, including those with Moderna, Emory University, Tiba Biotech, and others [2].

The wind-down includes the cancellation of BARDA’s award to Moderna for an mRNA-based H5N1 vaccine, as well as the termination of contracts with Emory University and Tiba Biotech. Additionally, the agency is de-scoping mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus, and rejecting or canceling multiple pre-award solicitations from companies like Pfizer, Sanofi Pasteur, CSL Seqirus, and Gritstone [2].

While some final-stage contracts, such as those with Arcturus and Amplitude, will be allowed to run their course to preserve prior taxpayer investment, no new mRNA-based projects will be initiated. HHS has also instructed its partner, Global Health Investment Corporation (GHIC), to cease all mRNA-based equity investments [2].

Secretary Kennedy emphasized that HHS supports safe and effective vaccines, stating, "We’re moving beyond the limitations of mRNA and investing in better solutions." The shift signals a broader change in federal vaccine development priorities, with BARDA focusing on platforms with stronger safety records and transparent clinical and manufacturing data practices [2].

This announcement is significant for investors and financial professionals, as it reflects a strategic realignment of resources within the federal health agency. The move underscores the importance of evidence-based, ethically grounded solutions in vaccine development and underscores the evolving nature of public health priorities.

References:
[1] Reuters. (2025). U.S. health agency to wind down mRNA vaccine development. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TX2KC:0-us-health-agency-to-wind-down-mrna-vaccine-development/
[2] U.S. Department of Health and Human Services. (2025). HHS winds down mRNA development under BARDA. Retrieved from https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html